Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hair dye/bladder cancer study

This article was originally published in The Rose Sheet

Executive Summary

The use of permanent hair dye does not increase risk for bladder cancer, according to a study in the September 2006 issue of Cancer Epidemiology Biomarkers and Prevention. Researchers at the University of Texas MD Anderson Cancer Center evaluated 712 bladder cancer cases and 712 age-, gender- and ethnicity-matched control cases and found that the use of permanent hair dye was not associated with bladder cancer risk in women or in men. The lack of association was not affected by "duration of use, frequency of use, lifetime use, age at first use, or color of use" in subsequent analyses. However, in 2005, the European Commission Scientific Committee on Consumer Products reaffirmed its opinion that women who frequently use permanent hair dyes may be at higher risk for bladder cancer (1"The Rose Sheet" Oct. 24, 2005, p. 3). A ban on the sale of 22 hair dye substances lacking safety data goes into effect Dec. 1 in the EU (2"The Rose Sheet" July 24, 2006, p. 7)...

You may also be interested in...



EU Hair Dye Ban On 22 Substances Effective In December

The European Commission has prohibited the sale of 22 hair dye substances for which no safety data exists under a ban that will go into effect Dec. 1, the commission announced July 20

Bladder Cancer Risk For U.S. Hair Dye Users Affirmed By SCCP

American women who use permanent hair dyes may be at a higher risk for bladder cancer, the European Commission Scientific Committee on Consumer Products concludes in a recent 1opinion

England’s NICE Recommends BMS/Celgene’s Revlimid For Follicular Lymphoma

Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.

UsernamePublicRestriction

Register

RS014368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel